WASHINGTON, IL--(Marketwired - May 21, 2013) - This little piggy went to market, this little piggy stayed home...for fear of revealing his ugly toenail. 40 million Americans struggle with unsightly toenails and many of them dread the summer months when feet are fully exposed at the pool or beach and sandals are the preferred footwear for many.
Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association
SOUTH SAN FRANCISCO, CA--(Marketwired - May 21, 2013) - Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentation of data highlighting Kyprolis® (carfilzomib) for Injection, a second-generation proteasome inhibitor, and oprozomib, an oral proteasome inhibitor in early development, at the 18th Congress of the European Hematology Association (EHA) Annual Meeting, June 13-16, 2013 in Stockholm, Sweden.
WASHINGTON, IL--(Marketwired - May 21, 2013) - This little piggy went to market, this little piggy stayed home...for fear of revealing his ugly toenail. 40 million Americans struggle with unsightly toenails, often feeling its wrath in the summer months. Thick, discolored toenails happen when fungus penetrates the nail bed and can occur for a litany of different reasons. Athletes who wear tight sneakers, women who wear pointy shoes, or ballerina slippers are just some of the likely victims.
SOUTH EASTON, MA--(Marketwired - May 21, 2013) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced financial results for the three-month period ended March 31, 2013 and provided a business update.
Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
SAN FRANCISCO, CA--(Marketwired - May 21, 2013) - Jennerex Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that it completed enrollment of 120 patients in the TRAVERSE study, a global randomized Phase 2b clinical trial evaluating the efficacy and safety of Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of advanced primary liver cancer (hepatocellular carcinoma, HCC) in patients who failed pri
PALO ALTO, CA--(Marketwired - May 21, 2013) - Ayasdi (www.ayasdi.com) today announced that it has received several industry awards in the last few weeks, just four months after its official company launch. The recognition reflects the excitement around Ayasdi's pioneering approach to helping solve some of the world's most complex and expensive problems such as cancer research, energy exploration, fraud detection, and terrorism prevention.
BAGSVAERD, DENMARK--(Marketwired - May 21, 2013) - On 3 May 2013, Novo Nordisk initiated a
share repurchase programme in accordance with the provisions of the
European Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules. This programme is part of the
overall share repurchase programme of up to DKK 14.0 billion to be executed
during a 12-month period beginning 31 January 2013.
NEW YORK, NY and PETACH TIKVAH, ISRAEL--(Marketwired - May 21, 2013) - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided an update on the company's current and upcoming clinical trial and scientific conference activities.
Clinical Trial Activities
PORT HUENEME, CA--(Marketwired - May 21, 2013) - Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that Frank Oaks, President & CEO and Darrell Brookstein, Executive VP, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel.
REDONDO BEACH, CA--(Marketwired - May 21, 2013) - ChromaDex Corporation (OTCQB: CDXC) Director Michael Brauser purchased 25,000 shares of common stock on the open market on May 13th, according to a Form 4 filing made with the SEC. These purchases took place at $0.662 per share, bringing the insider's total ownership stake to 4,519,926 shares owned directly by Mr. Brauser.